GlassScriptPhysician profile
Andrew N Bainnson
NPI 1669470829
$5,524.48
in general payments reported to CMS, 2019-2025
22 companies · $597 in 2025
The $597 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $341 · 2021: $266 · 2022: $987 · 2023: $1,305 · 2024: $1,126 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,027.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,029.22 | 2021-2025 | Clareon, Simbrinza, Eysuvis |
| Bausch & Lomb Americas INC. | $825.05 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Abbvie INC. | $622.78 | 2019-2025 | Durysta, Lumigan, Alphagan P |
| Allergan, INC. | $523.15 | 2019-2022 | |
| Oyster Point Pharma, INC. | $427.43 | 2022-2025 | Tyrvaya |
| Glaukos Corporation | $263.03 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $243.39 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $198.28 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $162.33 | 2019-2020 | |
| Rxsight INC | $154.94 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Shire North American Group INC | $149.01 | 2019 | |
| Harrow Eye, LLC | $130.57 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $127.85 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $125.00 | 2024 | Dextenza |
| Dompe US, INC. | $93.96 | 2022-2024 | Oxervate |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $86.28 | 2023-2025 | Cequa |
| Horizon Therapeutics Plc | $80.35 | 2019-2023 | Tepezza |
| Biotissue Holdings INC. | $72.75 | 2019-2024 | |
| Ani Pharmaceuticals, INC. | $67.47 | 2024-2025 | Purified Cortrophin Gel |
| Eyevance Pharmaceuticals LLC | $65.37 | 2019-2023 | Flarex |
| Boston Scientific Corporation | $53.58 | 2023 | |
| Amgen INC. | $22.69 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Bainnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.